MGen: How to Spot the Symptoms of This Under-the-Radar STD?

Is your genitourinary discomfort a sign of a sexually transmitted infection you may not have heard much about? Mycoplasma genitalium (often abbreviated M. genitalium or MGen) is a bacterial pathogen of increasing clinical importance. Although it was first identified several decades ago, recognition of its role in symptomatic urethritis, cervicitis and pelvic inflammatory disease has grown only recently, and diagnostic and management strategies continue to evolve. This article provides a clinical overview of M. genitalium: its epidemiology, common and uncommon symptoms, routes of transmission, diagnostic testing, treatment considerations (including antimicrobial resistance), complications, prevention strategies and guidance for patient counseling. Recommendations are framed using current guidance and summaries from major clinical resources (American College of Obstetricians and Gynecologists — ACOG; National Institutes of Health — NIH; Mayo Clinic; Cleveland Clinic).

Understanding Mycoplasma genitalium

Mycoplasma genitalium is a small, cell-wall–less bacterium that primarily colonizes the lower genitourinary tract. It has been implicated in non‑gonococcal urethritis in men and in cervicitis, endometritis and pelvic inflammatory disease (PID) in women. Because the organism is fastidious and requires specialized molecular techniques for reliable detection, it went under-recognized for many years. With the wider adoption of nucleic acid amplification tests (NAATs), detection rates and clinical awareness have increased (Mayo Clinic; NIH).

Source overview: Mayo Clinic — Mycoplasma genitalium; NIH — National Institute of Allergy and Infectious Diseases (NIAID) overviews.

Who is at risk?

M. genitalium infection can occur in sexually active people of any age or gender, but epidemiologic studies show higher prevalence in younger adults and those with multiple sexual partners or recent new partners. Prevalence estimates vary by population, geographic region and testing methods. Transmission occurs primarily through sexual contact involving the urethra, cervix and possibly rectal mucosa. The organism may also be transmitted between partners during genital contact. Because many infections are asymptomatic, infected individuals can unknowingly transmit the organism to partners (NIH; Cleveland Clinic).

Population risk factors: younger age, multiple partners, inconsistent barrier protection, previous or concurrent sexually transmitted infections.

Clinical presentation: symptoms in men and women

Clinical manifestations of M. genitalium are variable. Some infected persons develop clear symptoms of urethritis or cervicitis, while others remain asymptomatic. Symptoms are often nonspecific and overlap with other more commonly recognized infections such as Chlamydia trachomatis or Neisseria gonorrhoeae; therefore, targeted testing is necessary for diagnosis (Mayo Clinic; Cleveland Clinic).

Symptoms commonly reported in men

Urethral discomfort or dysuria (stinging or burning sensation when voiding)
Urethral discharge (clear to purulent)
Urethral itching or irritation
Less commonly: epididymal pain or inflammation if infection ascends

Symptoms of urethritis due to M. genitalium are clinically indistinguishable from urethritis caused by other organisms; consideration of M. genitalium is appropriate when common pathogens have been excluded or when symptoms persist despite usual therapy (Cleveland Clinic; Mayo Clinic).

Symptoms commonly reported in women

Abnormal vaginal discharge (may be increased or altered in character)
Cervicitis (inflammation of the cervical tissue), which may present with mucopurulent cervical discharge on exam
Dysuria (discomfort on urination)
Postcoital bleeding or intermenstrual spotting in some cases
Pelvic pain if infection ascends to the upper genital tract (endometritis or pelvic inflammatory disease)

Because symptoms in women can be subtle or overlap with other pelvic processes, a high index of suspicion is warranted in women with cervicitis, persistent vaginal symptoms or PID not explained by other pathogens (ACOG; Mayo Clinic).

Extragenital sites

M. genitalium DNA has also been detected in rectal specimens (particularly among men who have sex with men and individuals reporting receptive anal contact). Rectal infection can be asymptomatic or may cause proctitis-like symptoms. The role of oropharyngeal infection is less well defined and appears to be less common (NIH; review literature).

Asymptomatic infection: the silent threat

A substantial proportion of M. genitalium infections are asymptomatic. Asymptomatic carriage is clinically important because undiagnosed persons may transmit infection and because prolonged untreated infection may increase the risk of upper genital tract complications in women, such as pelvic inflammatory disease, infertility and ectopic pregnancy—although causality and magnitude of risk are still under investigation (Mayo Clinic; NIH).

How M. genitalium is transmitted

M. genitalium is transmitted primarily by sexual contact that exposes mucosal surfaces of the urethra, cervix or rectum to infected secretions. Transmission dynamics mirror those of other bacterial sexually transmitted infections:

Vaginal intercourse, genital-to-genital contact and receptive anal intercourse are recognized routes.
The risk of transmission increases with the number of sexual partners and with inconsistent or absent barrier protection.
Vertical (mother-to-infant) transmission and transmission via non-sexual routes have not been established as major pathways.

Partner notification and treatment are important elements of management to prevent reinfection and further spread (Cleveland Clinic; NIH).

Diagnostic testing: how MGen is identified

Because M. genitalium is difficult to culture, molecular diagnostics are the standard of care for detection.

Preferred tests

Nucleic acid amplification tests (NAATs) are the diagnostic method of choice. NAATs detect M. genitalium DNA or RNA in clinical specimens and are considerably more sensitive and specific than culture methods (Mayo Clinic; Cleveland Clinic).
Specimen types: First-void urine (men and women), vaginal swabs (self-collected or clinician-collected) for women, urethral swabs for men, and rectal swabs when rectal exposure is a concern. Endocervical swabs may be used in certain clinical settings.
Availability: NAAT availability varies by region and laboratory; clinicians should verify testing availability and specimen handling requirements.

Resistance testing

Molecular assays that detect mutations associated with macrolide resistance (typically 23S rRNA gene mutations) are increasingly available and can guide antibiotic selection. Detection of fluoroquinolone resistance–associated mutations (parC, gyrA) may also be possible in specialized laboratories (NIH; Mayo Clinic).
Phenotypic culture-based susceptibility testing is rarely available clinically due to technical difficulty.

When to test

Testing is indicated in symptomatic persons with urethritis, cervicitis, or persistent/recurrent symptoms after empiric therapy for more common pathogens.
Consider testing sexual contacts of persons with confirmed infection.
Routine screening of asymptomatic individuals is not universally recommended; clinical judgment and local guidelines should guide testing in higher-risk populations (ACOG; NIH).

Test-of-cure

A test-of-cure (repeat NAAT) is often recommended in cases with persistent symptoms, treatment failure or confirmed macrolide resistance. The timing of test-of-cure typically allows for clearance of nucleic acid after therapy (often recommended at least 3 weeks after completion of therapy), but local guidance and the specific regimen used influence timing (Mayo Clinic; Cleveland Clinic).

Treatment: antibiotic choices and resistance concerns

Management of M. genitalium is complicated by increasing antimicrobial resistance. Historically, macrolides (notably azithromycin) were used; however, macrolide resistance has risen substantially in many regions. Fluoroquinolones (moxifloxacin) may be used for macrolide-resistant or persistent infections, but fluoroquinolone resistance has also been reported. Treatment strategies should incorporate local resistance patterns and, when available, molecular resistance testing.

General principles

Confirm diagnosis with NAAT when possible before targeted therapy, particularly in cases where empiric therapy may be ineffective due to resistance.
If molecular testing for macrolide resistance is available, results should inform initial therapy.
In suspected or confirmed macrolide-resistant infection, alternative regimens are indicated.
Test-of-cure is recommended in cases of suspected or confirmed resistance or persistent symptoms.

Commonly used agents (clinical summary)

Macrolides: Azithromycin has been used historically; resistance due to mutations in the 23S rRNA gene reduces efficacy in many settings. Extended azithromycin regimens have improved some outcomes compared with single-dose strategies in certain contexts, but local resistance rates should guide use (Mayo Clinic; Cleveland Clinic).
Fluoroquinolones: Moxifloxacin is frequently used for macrolide-resistant or persistent infection; therapeutic courses and success rates vary and resistance has been reported (NIH; Cleveland Clinic).
Tetracyclines: Doxycycline has lower efficacy against M. genitalium when used as monotherapy but may be used as an initial regimen in some settings or as part of combination or sequential strategies to reduce organism load prior to other agents. Evidence supports lower cure rates with doxycycline alone (medical literature; NIH reviews).

Because treatment recommendations are evolving with emerging resistance patterns, clinicians are encouraged to consult current national guidance and infectious disease or sexual health specialists when managing confirmed or complicated cases (ACOG; NIH; Mayo Clinic).

Antimicrobial resistance: a growing challenge

Antimicrobial resistance in M. genitalium is a significant and growing global problem:

Macrolide resistance: Reported rates of macrolide resistance-associated mutations have increased substantially in many parts of the world, leading to higher rates of treatment failure with azithromycin (NIH; Mayo Clinic).
Fluoroquinolone resistance: Emerging resistance to fluoroquinolones (including moxifloxacin) compromises second-line treatment options in some regions.
Clinical implications: Resistance necessitates judicious antibiotic use, resistance-guided therapy when possible, partner treatment strategies, and close follow-up to confirm cure.

Public health efforts include monitoring resistance patterns, improving access to resistance testing, and research into new therapeutic options (NIH; ACOG summaries).

Complications and long-term consequences

Untreated or inadequately treated M. genitalium infection can be associated with complications, particularly in women:

Pelvic inflammatory disease (PID): M. genitalium has been implicated as one of several bacterial causes of PID. PID may result in chronic pelvic pain, tubal damage and risk of infertility.
Infertility and ectopic pregnancy: Upper genital tract infection and tubal scarring can contribute to infertility and increase ectopic pregnancy risk; the precise attributable risk from M. genitalium compared with other pathogens is under investigation.
Adverse pregnancy outcomes: Some studies suggest associations between M. genitalium and adverse pregnancy outcomes (e.g., preterm birth), but evidence is variable and causality is not definitively established.
Recurrent or persistent symptomatic infection: Repeated or unresolved infections can cause ongoing morbidity and psychosocial distress.

Early recognition, appropriate therapy and partner management aim to reduce the risk of these complications (Mayo Clinic; NIH; ACOG).

Special populations and considerations

Pregnancy

Data on M. genitalium in pregnancy are limited. Associations with adverse pregnancy outcomes have been suggested in some studies, but evidence is not conclusive. Antibiotic selection in pregnancy must balance efficacy against safety considerations for the fetus; clinicians should consult obstetric guidance and infectious disease specialists when managing M. genitalium in pregnancy (ACOG; NIH).

Adolescents and young adults

Young persons may have higher prevalence rates. Confidentiality, sensitive counseling, and age-appropriate sexual health education and prevention strategies are essential.

Men who have sex with men (MSM)

Rectal infection can occur and may be asymptomatic. When testing is performed in this population, rectal sampling should be considered if there has been receptive anal exposure (Cleveland Clinic; NIH).

Persons living with HIV

Co-infection can occur. Management should consider potential drug interactions and immune status; consultation with infectious disease specialists may be appropriate.

Prevention: reducing risk of acquisition and transmission

Prevention strategies focus on reducing exposure and increasing early detection:

Barrier protection: Consistent and correct use of condoms or other barrier methods reduces (but does not eliminate) risk of transmission.
Limiting number of sexual partners and avoiding concurrent partnerships reduces exposure risk.
Routine sexual health screening: Regular testing for common sexually transmitted infections in sexually active individuals and targeted testing for M. genitalium in symptomatic persons or in settings with high prevalence.
Partner notification and treatment: Sexual partners of persons with confirmed infection should be notified, evaluated and managed according to clinical guidance to prevent reinfection and onward transmission.
Education: Counseling about signs and symptoms, the potential for asymptomatic infection, and the importance of timely evaluation when symptoms occur.

No vaccine is available for M. genitalium. Public health strategies emphasize safer-sex practices, testing and treatment (CDC parallels; Mayo Clinic).

Counseling patients: practical points for clinicians

When discussing M. genitalium with patients, clear, nonjudgmental, evidence-based counseling promotes adherence and decreases transmission risk:

Explain the organism and how it is transmitted in factual, non-graphic language.
Discuss the possibility of asymptomatic infection and the rationale for testing if symptoms are present or after exposure.
Review the proposed diagnostic testing plan (type of sample, test method) and the expected timeline for results.
If treatment is prescribed, explain the importance of completing the full antibiotic course, potential side effects, and the need to avoid sexual activity until treatment (and any partner treatment) is completed and symptoms have resolved.
Emphasize partner notification and offer resources or referral for partner services when available.
Explain the need for follow-up testing if indicated (test-of-cure) and for reassessment if symptoms persist or recur.
Address emotional and relationship concerns; provide referrals for counseling if needed.

Public health and research directions

Surveillance: Continued monitoring of M. genitalium prevalence and antimicrobial resistance patterns is critical to inform treatment guidance.
Diagnostic access: Broader availability of NAATs and resistance assays will improve targeted therapy.
Therapeutic research: Development of new antimicrobials and optimized treatment algorithms are active areas of research given rising resistance.
Clinical guidance evolution: Professional societies and public health agencies update recommendations as new evidence emerges; clinicians should consult current guidance from organizations such as ACOG and NIH.

Frequently asked questions (FAQs)

Q: Can a routine STI panel detect M. genitalium? A: Many standard STI panels test for chlamydia and gonorrhea but do not always include M. genitalium unless specifically ordered. If M. genitalium is a clinical concern, a separate NAAT for this organism should be requested (Mayo Clinic; Cleveland Clinic).

Q: If my partner is treated, do I still need testing? A: Yes. Sexual partners of persons with confirmed infection should be evaluated and treated as appropriate. In many cases, testing and presumptive treatment of partners is recommended to prevent reinfection. Discuss partner management with your clinician (NIH; ACOG).

Q: How soon after treatment can I resume sexual activity? A: Patients are advised to refrain from sexual activity with unprotected genital or rectal contact until treatment is completed and any partner treatment has been completed. Recommendations on timing may vary by regimen and clinical situation; follow your clinician’s specific guidance.

Q: Is reinfection common? A: Reinfection can occur if sexual partners are not treated or if new exposures occur. Partner treatment and prevention counseling are important to reduce reinfection risk.

Q: Are there long-term health consequences? A: Untreated M. genitalium may be associated with pelvic inflammatory disease in women and with other complications that can affect reproductive health. Early detection and appropriate treatment reduce these risks.

Key takeaways

Mycoplasma genitalium is a sexually transmitted bacterium increasingly recognized as a cause of urethritis, cervicitis and pelvic inflammatory disease.
Symptoms are often nonspecific and overlap with other genital infections; a substantial proportion of infections are asymptomatic.
Diagnosis relies on nucleic acid amplification tests (NAATs); molecular resistance testing (macrolide and, in some centers, fluoroquinolone markers) can guide therapy.
Antimicrobial resistance, particularly to macrolides, is an evolving clinical challenge; effective management may require resistance-guided treatment and specialist consultation.
Prevention emphasizes barrier methods, limiting exposures, partner treatment and prompt evaluation of symptoms.
Clinicians should stay current with guidance from professional organizations and local public health agencies as diagnostic and treatment recommendations change with emerging evidence.

For further reputable information and clinician resources, consult:

American College of Obstetricians and Gynecologists (ACOG): clinical resources on sexually transmitted infections — https://www.acog.org
National Institutes of Health (NIH) / NIAID: Mycoplasma genitalium research and summaries — https://www.niaid.nih.gov
Mayo Clinic: Patient-oriented overview of Mycoplasma genitalium — https://www.mayoclinic.org
Cleveland Clinic: Clinical information on M. genitalium — https://my.clevelandclinic.org

If you have symptoms or concerns about possible infection, seek evaluation from a healthcare provider or local sexual health clinic. Timely assessment, appropriate testing and evidence-based management reduce the risk of complications and transmission.